Literature DB >> 18757409

BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.

Karen H Ventii1, Narra S Devi, Kenneth L Friedrich, Tatiana A Chernova, Mourad Tighiouart, Erwin G Van Meir, Keith D Wilkinson.   

Abstract

BRCA1-associated protein-1 (BAP1), a deubiquitinating enzyme of unknown cellular function, is mutated in breast and lung cancers. In this study, we have shown for the first time that BAP1 has tumor suppressor activity in vivo by showing that BAP1 can suppress tumorigenicity of lung cancer cells in athymic nude mice. We show that BAP1 fulfills another criterion of a genuine tumor suppressor because cancer-associated BAP1 mutants are deficient in deubiquitinating activity. We show for the first time that one of the two predicted nuclear targeting motifs is required for nuclear localization of BAP1 and that a truncation mutant found in a lung cancer cell line results in BAP1 that fails to localize to the nucleus. Furthermore, we show that deubiquitinating activity and nuclear localization are both required for BAP1-mediated tumor suppression in nude mice. We show that BAP1 exerts its tumor suppressor functions by affecting the cell cycle, speeding the progression through the G(1)-S checkpoint, and inducing cell death via a process that has characteristics of both apoptosis and necrosis. Surprisingly, BAP1-mediated growth suppression is independent of wild-type BRCA1. Because deubiquitinating enzymes are components of the ubiquitin proteasome system, this pathway has emerged as an important target for anticancer drugs. The identification of the deubiquitinating enzyme BAP1 as a tumor suppressor may lead to further understanding of how the ubiquitin proteasome system contributes to cancer and aid in the identification of new targets for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757409      PMCID: PMC2736608          DOI: 10.1158/0008-5472.CAN-08-0365

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 2.  Regulation of ubiquitin-dependent processes by deubiquitinating enzymes.

Authors:  K D Wilkinson
Journal:  FASEB J       Date:  1997-12       Impact factor: 5.191

3.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.

Authors:  D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

4.  Identification of nude mice in tumorigenicity assays.

Authors:  E G van Meir
Journal:  Int J Cancer       Date:  1997-04-10       Impact factor: 7.396

Review 5.  Roles of ubiquitinylation in proteolysis and cellular regulation.

Authors:  K D Wilkinson
Journal:  Annu Rev Nutr       Date:  1995       Impact factor: 11.848

6.  Deubiquitinating enzyme purification, assay inhibitors, and characterization.

Authors:  Nathaniel S Russell; Keith D Wilkinson
Journal:  Methods Mol Biol       Date:  2005

Review 7.  The ubiquitin-proteasome pathway and its role in cancer.

Authors:  Aparna Mani; Edward P Gelmann
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

8.  Homozygous deletion, rearrangement and hypermethylation implicate chromosome region 3p14.3-3p21.3 in sporadic breast-cancer development.

Authors:  D L Buchhagen; L Qiu; P Etkind
Journal:  Int J Cancer       Date:  1994-05-15       Impact factor: 7.396

9.  Both DNA topoisomerase II-binding protein 1 and BRCA1 regulate the G2-M cell cycle checkpoint.

Authors:  Kazuhiko Yamane; Junjie Chen; Timothy J Kinsella
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

Review 10.  Ubiquitin and breast cancer.

Authors:  Tomohiko Ohta; Mamoru Fukuda
Journal:  Oncogene       Date:  2004-03-15       Impact factor: 9.867

View more
  131 in total

Review 1.  Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Authors:  Sebastian Walpole; Antonia L Pritchard; Colleen M Cebulla; Robert Pilarski; Meredith Stautberg; Frederick H Davidorf; Arnaud de la Fouchardière; Odile Cabaret; Lisa Golmard; Dominique Stoppa-Lyonnet; Erin Garfield; Ching-Ni Njauw; Mitchell Cheung; Joni A Turunen; Pauliina Repo; Reetta-Stiina Järvinen; Remco van Doorn; Martine J Jager; Gregorius P M Luyten; Marina Marinkovic; Cindy Chau; Miriam Potrony; Veronica Höiom; Hildur Helgadottir; Lorenza Pastorino; William Bruno; Virginia Andreotti; Bruna Dalmasso; Giulia Ciccarese; Paola Queirolo; Luca Mastracci; Karin Wadt; Jens Folke Kiilgaard; Michael R Speicher; Natasha van Poppelen; Emine Kilic; Rana'a T Al-Jamal; Irma Dianzani; Marta Betti; Carsten Bergmann; Sandro Santagata; Sonika Dahiya; Saleem Taibjee; Jo Burke; Nicola Poplawski; Sally J O'Shea; Julia Newton-Bishop; Julian Adlard; David J Adams; Anne-Marie Lane; Ivana Kim; Sonja Klebe; Hilary Racher; J William Harbour; Michael L Nickerson; Rajmohan Murali; Jane M Palmer; Madeleine Howlie; Judith Symmons; Hayley Hamilton; Sunil Warrier; William Glasson; Peter Johansson; Carla Daniela Robles-Espinoza; Raul Ossio; Annelies de Klein; Susana Puig; Paola Ghiorzo; Maartje Nielsen; Tero T Kivelä; Hensin Tsao; Joseph R Testa; Pedram Gerami; Marc-Henri Stern; Brigitte Bressac-de Paillerets; Mohamed H Abdel-Rahman; Nicholas K Hayward
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

2.  Ubiquitination: Added complexity in Ras and Rho family GTPase function.

Authors:  Michelle de la Vega; James F Burrows; James A Johnston
Journal:  Small GTPases       Date:  2011-07-01

3.  Germline BAP1 mutations and tumor susceptibility.

Authors:  Alisa M Goldstein
Journal:  Nat Genet       Date:  2011-09-28       Impact factor: 38.330

Review 4.  Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.

Authors:  Key-Hwan Lim; Myoung-Hyun Song; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2016-01-13       Impact factor: 9.261

5.  Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.

Authors:  Michele Carbone; Haining Yang
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 6.  BAP1, a tumor suppressor gene driving malignant mesothelioma.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 7.  Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.

Authors:  Francisca E Reyes-Turcu; Karen H Ventii; Keith D Wilkinson
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

8.  Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.

Authors:  Anna K Nowak
Journal:  Ann Cardiothorac Surg       Date:  2012-11

9.  BAP1 is phosphorylated at serine 592 in S-phase following DNA damage.

Authors:  Ziad M Eletr; Luming Yin; Keith D Wilkinson
Journal:  FEBS Lett       Date:  2013-11-05       Impact factor: 4.124

10.  Global transcriptomic analysis of model human cell lines exposed to surface-modified gold nanoparticles: the effect of surface chemistry.

Authors:  E M Grzincic; J A Yang; J Drnevich; P Falagan-Lotsch; C J Murphy
Journal:  Nanoscale       Date:  2015-01-28       Impact factor: 7.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.